<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8" />
<title>Shared Decision Making</title>
<meta name="description" content="Shared Decision Making by the NHS" />
<meta name="google-site-verification" content="0lYrbORCRFYBpi4yE-WNVJIJ0KRNKHKFrHQPxht2MIQ" />
<link href="../../../favicon.ico" rel="favicon" >
<link href="../../../external/javascript/reset-fonts-grids.css" media="screen" rel="stylesheet" type="text/css" >
<link href="../../../external/jquery-ui/jquery-ui-1.8.18.custom.css" media="screen" rel="stylesheet" type="text/css" >
<link href="../../../external/fancybox/jquery.fancybox.css" media="screen" rel="stylesheet" type="text/css" >
<link href="../../../styles/screen9756.css" media="screen,mobile" rel="stylesheet" type="text/css" >
<script type="text/javascript" src="../../../external/jquery/jquery-1.7.1.js"></script>
<script type="text/javascript" src="../../../external/jquery-ui/jquery-ui-1.8.18.custom.min.js"></script>
<script type="text/javascript" src="../../../external/fancybox/jquery.fancybox.pack.js"></script>
<script type="text/javascript" src="../../../javascript/jwplayer.js"></script>
<script type="text/javascript" src="../../../javascript/site9756.js"></script>
</head>
<body class="">
<div id="custom-doc" class="pda"> <!-- start yui doc -->
<div id="hd"> <!-- start yui hd -->
<noscript>
  <meta http-equiv="refresh" content="0;url=/no-javascript">
</noscript>
<a class="skip-links" href="#navigation-start" title="Skip to the main site navigation">Skip to site navigation</a>
<a class="skip-links" href="#content-start" title="Skip to the main content on this page">Skip to content</a>
<!--[if gte IE 9]>
    <style type="text/css">
        .gradient {
            filter: none;
        }
    </style>
<![endif]-->
<div id="header">
    <div id="pda-head-strip">
                <div class="page-header">
            <h1 class="title pda-title nhs-dark-blue inline-block">DIABETES: ADDITIONAL TREATMENTS TO IMPROVE CONTROL</h1>
            <a id="home-link" class="inline-block frutiger" href="../../../index.html" title="Leave this decision aid and return to the main site">CLOSE</a>
                    
                </div>
        <a id="pda-navigation-start"></a>
<div class="main-nav tab-titles" role="navigation"><!--
                                --><div class="title inline-block complete">
                <span class="tab-no"></span>
                <div class="link">
            <a href="../introduction/index.html" title="Decision Aid Step 1: Introduction">INTRODUCTION</a>            <div class="desc"?>Overview of the decision, options and health problem.</div>
        </div>
        <div class="tail"></div>
   </div><!--
                                   --><div class="title inline-block complete">
                <span class="tab-no"></span>
                <div class="link">
            <a href="../compare-options/index.html" title="Decision Aid Step 2: Compare Options">COMPARE OPTIONS</a>            <div class="desc"?>Information about all the options explained side-by-side.</div>
        </div>
        <div class="tail"></div>
   </div><!--
                                   --><div class="title inline-block current">
                <span class="tab-no">3</span>
                <div class="link">
            <a href="index.html" title="Decision Aid Step 3: My Values">MY VALUES</a>            <div class="desc"?>Thinking about what matters to you about the decision.</div>
        </div>
        <div class="tail"></div>
   </div><!--
                                   --><div class="title inline-block">
                <span class="tab-no">4</span>
                <div class="link">
            <a href="/my-trade-offs/index.html" title="Decision Aid Step 4: My Trade-offs">MY TRADE-OFFS</a>            <div class="desc"?>Weighing-up the pros and cons of the options to you.</div>
        </div>
        <div class="tail"></div>
   </div><!--
                                   --><div class="title inline-block">
                <span class="tab-no">5</span>
                <div class="link">
            <a href="../my-decision/index.html" title="Decision Aid Step 5: My Decision">MY DECISION</a>            <div class="desc"?>Make a decision that is right for you at this time</div>
        </div>
        <div class="tail"></div>
   </div><!--
               -->
</div>
    </div>
</div></div> <!-- end yui hd -->

<div id="bd"> <!-- start yui bd -->
<div class="yui-g">
<div id="body" class="my-values">
<div class="help-content embedded">
        <div class="tab-body">
        <div id="close-help-top" class="close-help frutiger" role="button">CLOSE HELP</div>
        <div id="video-content" role="tabpanel" aria-hidden="true" aria-describedby="video-tab" class="">
            <div class="col left-col"><p>The video guides in this section will help explain how to use a Decision Aid. &nbsp;</p>
<p>Each video is no more than 2 minutes long and there is one video for each step in the process.</p>
<p>You can come back to view them at any time by clicking on the "HELP" bar when viewing a Decision Aid.</p></div><!--
         --><div class="col right-col"><h3 class="video-title"></h3><div id="video-stage"></div></div>
            <h3 class="title">OTHER VIDEOS</h3>
            <div class="video-listing">
                                                <div class="video-item inline-block" data-s3-filename="tour-step1.mp4" data-preview-image="../../../public/cms/150/318/162/305/3GF4RS_web.png" id='play-introduction'>
                    <img role="button" title="Play Step 1: Introduction video" src="../../../public/cms/150/318/162/305/3GF4RS_130x100.png" width="160" height="95" alt="Step 1: Introduction Video Guide" />
                    <!-- div class="overlay"></div -->
                    <h4 class="title">STEP 1: INTRODUCTION</h4>
                </div>
                                <div class="video-item inline-block" data-s3-filename="tour-step2.mp4" data-preview-image="../../../public/cms/150/318/162/305/NtsY5A_web.png" id='play-compare-options'>
                    <img role="button" title="Play Step 2: Compare Options video" src="../../../public/cms/150/318/162/305/NtsY5A_130x100.png" width="160" height="95" alt="Step 2: Compare Options Video Guide" />
                    <!-- div class="overlay"></div -->
                    <h4 class="title">STEP 2: COMPARE OPTIONS</h4>
                </div>
                                <div class="video-item inline-block" data-s3-filename="tour-step3.mp4" data-preview-image="../../../public/cms/150/318/162/305/hyk52k_web.png" id='play-your-views'>
                    <img role="button" title="Play Step 3: My Views video" src="../../../public/cms/150/318/162/305/hyk52k_130x100.png" width="160" height="95" alt="Step 3: Your Views Video Guide" />
                    <!-- div class="overlay"></div -->
                    <h4 class="title">STEP 3: MY VIEWS</h4>
                </div>
                                <div class="video-item inline-block" data-s3-filename="tour-step4.mp4" data-preview-image="../../../public/cms/150/318/162/305/xHk8u6_web.png" id='play-trade-offs'>
                    <img role="button" title="Play Step 4: My Trade-offs video" src="../../../public/cms/150/318/162/305/xHk8u6_130x100.png" width="160" height="95" alt="Step 4: Trade-offs Video Guide" />
                    <!-- div class="overlay"></div -->
                    <h4 class="title">STEP 4: MY TRADE-OFFS</h4>
                </div>
                                <div class="video-item inline-block" data-s3-filename="tour-step5.mp4" data-preview-image="../../../public/cms/150/318/162/305/Ze4toT_web.png" id='play-your-decision'>
                    <img role="button" title="Play Step 5: My Decision video" src="../../../public/cms/150/318/162/305/Ze4toT_130x100.png" width="160" height="95" alt="Step 5: Your Decision Video Guide" />
                    <!-- div class="overlay"></div -->
                    <h4 class="title">STEP 5: MY DECISION</h4>
                </div>
                                            </div>
        </div>
        <div id="coaching-content" role="tabpanel" aria-hidden="true" aria-describedby="video-content" class="">
            <div class="col left-col"><p>Our Decision Support telephone service is here to&nbsp;assist and guide you through the Shared Decision Making process.</p>
<p>The Decision Support team is made of professional Health Coaches who are&nbsp;clinicians, commonly nurses, who have undertaken additional training to become a Health Coach.</p>
<p>The Health Coaches will assist you by:</p>
<ul>
<li>Providing you with information</li>
<li>Helping you to understand your condition</li>
<li>Recognise what is important to you regarding the outcome of treatment</li>
<li>Identifying potential solutions</li>
<li>Encourage you in discussing options with your family</li>
<li>Transferring skills which will assist you in using the information and resources available to you</li>
<li>Support you in building confidence in discussing your choice with your doctor</li>
<li>You may find that this can be achieved in one telephone call with a Health Coach however; if further calls are required to support you in reaching your decision the Health Coach will schedule these with you.</li>
</ul>
<p class="further-info-sub-heading">Important Things To Note</p>
<ul>
<li>A Health Coach does not know which treatment option is best for you.</li>
<li>The Health Coach does not have information about your medical history.</li>
<li>You will still need to talk over your decision and reasons for your decision with your doctor or nurse.</li>
</ul>
<p class="further-info-sub-heading">Hours Of Operation</p>
<p>Our Decision Support service runs from 9am - 5:30pm Monday to Friday</p></div><!--
         --><div class="col right-col">
                                        <img src="../../../public/cms/150/318/162/305/uTt85Y_web.jpg" width="300" height="199" alt="Health Coach" />
                                <div class="telephone">
                    <div class="number frutiger">SPEAK TO A HEALTH COACH <a href="tel:0845 450 5851" title="Speak to a health coach">0845 450 5851</a></div>
                    <div class="icon"></div>
                </div>
                            </div>
        </div>
        <div id="map-content" role="tabpanel" aria-hidden="true" aria-describedby="video-content" class="">
            <div class="decision-map-tab">
                <p>The decision map below shows you which Decision Aid you currently using and the options you are making a decision about. &nbsp;It also shows you how this decision links with other choices for <strong>Diabetes: Additional treatments to improve control</strong>.</p>                <div id="decision-map-content">
                                        <img class="inline-block" src="../../../public/cms/150/318/624/1659/9oYuGo_web.png" width="765" height="500" alt="poorly-controlled-type-2-diabetes-x4.png" />
                    <div id="map-legend" class="inline-block">
                        <h3>LEGEND</h3>
                        <div class="current">
                            <p class="frutiger">CURRENT DECISION AID</p>
                        </div>
                        <div class="your-options no-related">
                            <h4 class="title">YOUR OPTIONS</h4>
                        </div>
                                            </div>
                </div>
            </div>
        </div>
        <div id="close-help-bottom" class="close-help frutiger" role="button">CLOSE HELP</div>
    </div>
    </div>    <div id="pda">
        <div id="hover-wrap">
    <div class="arrow"></div>
    <div class="content-container">
        <div class="content"></div>
    </div>
</div><div class="tab-content">
            <a id="content-start" data-cms-content-id=""></a>
            
<div class="header">
    <div class="step frutiger">3</div>
    <h1 class="step-title frutiger">My Values</h1>
    <div class="desc">Thinking about what matters to you about the decision.</div>
</div>

<div id="help-key-facts" class="closed">
    <div role="button" id="help-key-facts-btn" class="frutiger">
        KEY INFORMATION / HELP
    </div>
    <div class="help-key-facts-content" aria-hidden="false">
        <div class="help-key-facts-inner">
            <div id="help-more-info" role="button" class="frutiger button">More information about Diabetes: Additional treatments to improve control</div>
                        <div id="help-options" class="frutiger">
                <div>Learn more about the options available:</div>
                <div class="items">
                                    <div role="button" class="button frutiger" data-option-info="container-1635">Insulin</div>
                                    <div role="button" class="button frutiger" data-option-info="container-1633">GLP-1 analogues</div>
                                    <div role="button" class="button frutiger" data-option-info="container-1634">Pioglitazone</div>
                                    <div role="button" class="button frutiger" data-option-info="container-1632">DDP-4 inhibitors</div>
                                </div>
            </div>
                                    <div id="help-animation" class="title frutiger button" data-animation-file="diabetes_additional_treatments_v_1.m4v">Animation about Diabetes: Additional treatments to improve control</div>
                        <div id="help-decision-map" role="button" class="frutiger button help-trigger" aria-controls="map-content">Decision Map for Diabetes: Additional treatments to improve control</div>
             </div>
    </div>
</div>
         
<div id="help-key-facts-dyn-content" aria-hidden="true">
<div class="detach-further-info">
    <div class="further-information" id="more-info">
        <h3 class="title">MORE INFORMATION ABOUT DIABETES: ADDITIONAL TREATMENTS TO IMPROVE CONTROL</h3>
        <dl class="tabbed-container" role="tablist">
                            <dt class="title" role="tab" aria-controls="content-1636-1" tabindex="0" id="title-1636-1">What is poorly controlled Type 2 diabetes?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1636-1" aria-describedby="title-1636-1">
                <div data-cms-content-id="349_1_further-info_1636"><p>Type 2 diabetes is poorly controlled when the treatment a person is taking is not keeping their blood glucose down to safe levels.</p>
<p>Glucose control is indicated by a blood test called an HbA1c level. An HbA1c level over 58mmol/mol (7.5%) may increase the chance of getting complications in future.</p>
<p>If a person's blood glucose levels remain high they may have a higher chance of getting serious health problems in future. These include damage to the eyes, nerves or kidneys, as well as heart disease and stroke.</p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1733-2" tabindex="0" id="title-1733-2">What are the symptoms of poorly controlled Type 2 diabetes?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1733-2" aria-describedby="title-1733-2">
                <div data-cms-content-id="349_1_further-info_1733"><p>Most people with poorly controlled Type 2 diabetes don&rsquo;t get symptoms, but some do.</p>
<p>The main symptoms of high blood glucose levels are being thirsty, needing to urinate often, feeling tired and have lots of infections, such as thrush.&nbsp;[<span class="referenceLink" id="referenceLink-1">1</span>]<span id="reference-1" class="content-reference">NHS Choices. Hyperglycaemia &ndash; symptoms, 2012</span></p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1637-3" tabindex="0" id="title-1637-3">How do I know I have poorly controlled Type 2 diabetes?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1637-3" aria-describedby="title-1637-3">
                <div data-cms-content-id="349_1_further-info_1637"><p>People with Type 2 diabetes have their blood glucose levels measured every 3-6 months using a test called HbA1C.</p>
<p>This shows how much glucose (sugar) has &lsquo;stuck&rsquo; to the red blood cells in the bloodstream and other important parts of the body, such as the eyes, kidneys, nerves and blood vessels.</p>
<p>HbA1c looks at blood glucose levels over the last 8-12 weeks and so is a good measure of overall diabetes control.</p>
<p>People with an HbA1c between 48 and 58mmol/mol have the lowest risk of getting complications in future. These numbers are sometimes given as percentages, when the safest level is between 6.5 and 7.5 per cent.</p>
<p>Levels over 58mmol/mol (7.5%) may increase the chance of getting complications in future. These include damage to the eyes, nerves or kidneys, as well as heart disease and stroke.</p>
<p>Levels under 48mmol/mol (6.5%), which can happen with some medications, may increase the chance of having low blood sugars, known as hypoglycaemic episodes, or hypos. When this happens a person may feel shaky, weak and hungry. A really severe hypo can cause drowsiness and confusion, or even loss of consciousness. Fortunately this is rare.</p>
<p>People with Type 2 diabetes usually agree their own safest HbA1c level with their diabetes care team. Usually this will be between 48 and 58mmol/mol (6.5-7.5%).&nbsp;[<span class="referenceLink" id="referenceLink-2">2</span>]<span id="reference-2" class="content-reference">NICE Quality standard for diabetes in adults, March 2011</span></p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1639-4" tabindex="0" id="title-1639-4">What will happen if my diabetes is not under control?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1639-4" aria-describedby="title-1639-4">
                <div data-cms-content-id="349_1_further-info_1639"><p>People with Type 2 diabetes have a higher chance of getting other serious health problems in the long term. Having poor control makes these complications more likely.</p>
<p>The main health problems linked with diabetes are&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span>:</p>
<ul>
<li>Eye damage that can lead to blindness</li>
<li>Kidney damage that can be severe enough to need dialysis or a transplant</li>
<li>Damage to the neurological system, especially nerves in the legs and feet. In really bad cases this can lead to amputation</li>
<li>Heart disease, including angina and heart attacks</li>
<li>Poor blood flow to other parts of the body, particularly the legs. This is called peripheral artery disease. In really bad cases it is sometimes necessary to have a leg or foot amputated</li>
<li>Stroke, when blood flow to the brain is blocked.</li>
</ul>
<p>It is common for people to experience a combination of these health problems at the same time. Higher glucose levels make serious health problems more likely. The chance of dying from them is much higher with HbA1c levels over 64-75mmol/mol (8-9%)&nbsp;[<span class="referenceLink" id="referenceLink-4">4</span>]<span id="reference-4" class="content-reference">Yudkin JS, Richter B, Gale EAM. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 2010; 53: 2079-85</span>.</p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1736-5" tabindex="0" id="title-1736-5">What will happen if I improve my control?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1736-5" aria-describedby="title-1736-5">
                <div data-cms-content-id="349_1_further-info_1736"><p>Keeping blood glucose down to safe levels makes people less likely to get long term health problems like damage to the eyes, kidneys or nerves, as well as heart disease and stroke.</p>
<p>Reducing HbA1c levels by just 10mmol/mol (1%) cuts the chance of getting these problems by 21 per cent (just over a fifth).&nbsp;[<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span>&nbsp;But bringing HbA1c levels down to below 53mmol/mol (7%) may not give any additional benefit and can make hypos more likely.&nbsp;[<span class="referenceLink" id="referenceLink-6">6</span>]<span id="reference-6" class="content-reference">Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2549-59] ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72</span>&nbsp;[<span class="referenceLink" id="referenceLink-7">7</span>]<span id="reference-7" class="content-reference">Duckworth W, Albaira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2008;360:129-39</span></p>
<p>People with Type 2 diabetes may live longer if they can keep their HbA1c levels to around 58mmol/mol, or 7.5%. Blood glucose levels that are lower or higher than this may reduce life expectancy.&nbsp;[<span class="referenceLink" id="referenceLink-8">8</span>]<span id="reference-8" class="content-reference">Currie CJ, Peters JR, Tynan A. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-89</span></p>
<p>Better diabetes control may improve people&rsquo;s quality of life in the long term by reducing the chance of complications and other health problems.</p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1640-6" tabindex="0" id="title-1640-6">How can I improve my diabetes control with medication?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1640-6" aria-describedby="title-1640-6">
                <div data-cms-content-id="349_1_further-info_1640"><p>People with Type 2 diabetes can often control their blood glucose levels at first through lifestyle changes like healthy diet and exercise.</p>
<p>Over the years most people find they need more treatments to keep their blood glucose under control.&nbsp;[<span class="referenceLink" id="referenceLink-9">9</span>]<span id="reference-9" class="content-reference">NICE short clinical guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span></p>
<p>An important way to improve diabetes control is to take medication regularly, at the right times and in the right doses. Many people with Type 2 diabetes don&rsquo;t do this and so can&rsquo;t keep good control.</p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1641-7" tabindex="0" id="title-1641-7">How can I improve my diabetes control by making lifestyle changes?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1641-7" aria-describedby="title-1641-7">
                <div data-cms-content-id="349_1_further-info_1641"><p>There are some changes people can make to their lifestyle that can improve their diabetes control or reduce the chance of getting complications, or both.&nbsp;[<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;[<span class="referenceLink" id="referenceLink-11">11</span>]<span id="reference-11" class="content-reference">International Diabetes Federation. Global Guideline for type 2 diabetes, 2012</span></p>
<ul>
<li>Becoming more physically active. Taking regular exercise can improve blood glucose control, whether or not people lose weight.&nbsp;[<span class="referenceLink" id="referenceLink-12">12</span>]<span id="reference-12" class="content-reference">Thomas D, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus&nbsp;</span><span id="reference-12" class="content-reference">Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD002968</span>&nbsp;Aerobic exercise, such as brisk walking or swimming, and resistance exercise, such as weight training are both helpful, especially in combination. Being active every 2-3 days is best for diabetes control.&nbsp;[<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;[<span class="referenceLink" id="referenceLink-11">11</span>]<span id="reference-11" class="content-reference">International Diabetes Federation. Global Guideline for type 2 diabetes, 2012</span>&nbsp;But some physical activity is better than none and the more people do, the greater the benefit.</li>
<li>Reducing weight. Most people with type 2 diabetes are overweight, which makes them even more likely to get heart disease. Losing weight can help with glucose control as well as reducing the chance of heart disease. People can lose weight through a combination of diet and exercise. VLCD (very low calorie diet) meal replacements can be helpful with support from the diabetes team.&nbsp;Special weight loss drugs or surgery are sometimes recommended for very overweight people.</li>
<li>Improving diet. Eating healthily can help people lose weight and may also improve their diabetes control.&nbsp;</li>
</ul>
<p>People can do this by:&nbsp;[<span class="referenceLink" id="referenceLink-15">15</span>]<span id="reference-15" class="content-reference">Diabetes UK. Evidence-based nutrition guidelines for the prevention and management of diabetes. May 2011</span></p>
<ul>
<li>Taking in fewer calories overall,&nbsp;such as by cutting down on high-calorie foods and reducing portion sizes&nbsp;</li>
<li>Drinking less alcohol. Alcohol is high in calories and can increase people's chance of getting future health problems</li>
<li>Eating less fat, particularly saturated (animal) fat</li>
<li>Eating fewer carbohydrate foods</li>
<li>Choosing carbohydrates with a low rather than a high glycaemic index (GI). Foods with a high GI tend to release glucose more rapidly into the bloodstream. They include white bread, rice and potatoes. Low GI foods include beans, seeds, grains and most vegetables.</li>
</ul>
<p>Mediterranean-style diets that are high in&nbsp;fruit and vegetables, whole grains, legumes and nuts and low in butter and red meat have been shown to help with glucose control.&nbsp;[<span class="referenceLink" id="referenceLink-16">16</span>]<span id="reference-16" class="content-reference">Esposito K, Maiorino MI, Di Palo C, et al. Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes. Diabet Med 2009 Sep;26(9):900-7</span></p>
<p><span>Lifestyle change can be hard, but every effort counts and it can be helpful to start with small changes and build up. Support is available from diabetes teams.</span></p></div>
            </dd>
                                <dt class="title" role="tab" aria-controls="content-1642-8" tabindex="0" id="title-1642-8">What else can I do to avoid long term health problems?</dt>
            <dd class="further-info-tab-content" role="tabpanel" id="content-1642-8" aria-describedby="title-1642-8">
                <div data-cms-content-id="349_1_further-info_1642"><p>Improving diabetes control can help reduce the chance of complications and other health problems in the future.</p>
<p>For cigarette smokers, trying to give up can also make a difference. Having Type 2 diabetes means a person is more likely to get heart disease or stroke in future. Smoking increases that chance and giving up reduces it.</p>
<p>It may also be necessary to take extra medication to prevent future health problems. This may include:</p>
<ul>
<li>Drugs to reduce blood pressure. High blood pressure increases the chance of getting heart disease, stroke, eye and kidney damage. Taking one or more drugs to reduce blood pressure can reduce the risk of heart disease by 20-25% and stroke by 30-45%.&nbsp;[<span class="referenceLink" id="referenceLink-11">11</span>]<span id="reference-11" class="content-reference">International Diabetes Federation. Global Guideline for type 2 diabetes, 2012</span></li>
<li>Drugs to reduce blood fats. Having high levels of cholesterol and triglyceride fats in the blood makes people more likely to get heart disease. Statins can reduce cholesterol levels and drugs called fibrates can keep triglycerides down.&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
<li>Blood-thinning drugs. Low doses of aspirin (75mg a day) may be recommended for people thought to have a high chance of heart disease or stroke. A drug called clopidogrel can be used instead for people who can&rsquo;t take aspirin.&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul></div>
            </dd>
                            </dl>
    </div>
</div><div class="further-info-options">
        <div class="option-info-container" id="container-1635">
        <a id="option-1635-further-info">Further Information</a>
        <div class="insert-container">
            <div class="further-information">
                <h3 class="title">FURTHER INFORMATION ABOUT INSULIN</h3>
                <dl class="tabbed-container" id="info-1635" role="tablist">
                                                    <dt role="tab" aria-selected="false" aria-controls="content-1635-1" class="title" id="title-1635-1" tabindex="0">What is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-1" aria-describedby="title-1635-1" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_0"><p>Insulin injections replace the insulin made naturally in the body to control your blood glucose levels.<br />There are lots of different types of insulin and they all act in slightly different ways. [<span class="referenceLink" id="referenceLink-20">20</span>]<span id="reference-20" class="content-reference">Patient UK, Insulin</span>:</p>
<ul>
<li>Short-acting insulins work quickly and are usually injected just before meals</li>
<li>Intermediate and long-acting insulins take longer to work and the effects last longer</li>
<li>Biphasic insulins contain a mixture of short-acting and intermediate or long-acting insulin.</li>
</ul>
<p>All types of insulin are usually injected into the skin of the stomach, thigh or upper arm, using a syringe or injector pen. They can also be given continuously by pump infusion.</p>
<p>Some people with Type 2 diabetes need two or more injections a day, but many can manage very well with just one.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-2" class="title" id="title-1635-2" tabindex="0">Who can choose it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-2" aria-describedby="title-1635-2" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_1"><p>Anyone with Type 2 diabetes can choose to have insulin injections if their blood glucose levels are not well controlled on other treatments.</p>
<p>People already taking two other medications are encouraged to have insulin as their third treatment unless there is a good reason not to. [<span class="referenceLink" id="referenceLink-21">21</span>]<span id="reference-21" class="content-reference">NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span></p>
<p>Reasons not to take insulin might include:</p>
<ul>
<li>Concerns about &lsquo;hypos&rsquo;, when the blood sugar drops too low, and their impact on work and leisure</li>
<li>Concerns about injections</li>
<li>The need to avoid putting on weight.</li>
</ul>
<p>People with Type 2 diabetes usually start with a type of insulin called &lsquo;human NPH insulin&rsquo;. This is injected at bed time or twice a day, according to need.</p>
<p>Some people are offered once-daily treatment with a &lsquo;long-acting insulin analogue&rsquo;, such as insulin glargine or insulin detemir instead of NPH insulin. This may happen if:</p>
<ul>
<li>They have a lot of hypos</li>
<li>They can&rsquo;t use the device needed to inject NPH insulin</li>
<li>They would need two NPH injections a day as well as tablet treatments.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-3" class="title" id="title-1635-3" tabindex="0">How effective is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-3" aria-describedby="title-1635-3" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_2"><p>Insulin has been used for many years and is known to improve blood glucose control in Type 2 diabetes.</p>
<p>We know from research that this improved control translates into real health benefits.<br />People with Type 2 diabetes treated with insulin can reduce their chance of getting kidney, eye and nerve damage, as well as heart disease. [<span class="referenceLink" id="referenceLink-22">22</span>]<span id="reference-22" class="content-reference">Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomised prospective 6-year study. Diabetes Res Clin Prac 1995 May; 28(2):103-17</span> [<span class="referenceLink" id="referenceLink-23">23</span>]<span id="reference-23" class="content-reference">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12;352(9131):837-53</span> [<span class="referenceLink" id="referenceLink-24">24</span>]<span id="reference-24" class="content-reference">Holman RR, Paul SK, Bethel MA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-4" class="title" id="title-1635-4" tabindex="0">What are the main side effects?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-4" aria-describedby="title-1635-4" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_3"><p>The main possible side effects of insulin treatment are weight gain and an increased chance of hypoglycaemic episodes (&lsquo;hypos&rsquo;), when the blood sugar drops too low. Hypos can be prevented or treated by taking sugary food.</p>
<p>It is common for people with Type 2 diabetes who take insulin to gain between two and four kilograms (4.5 &ndash; 9lbs). This may be because of extra snacking to prevent or treat hypoglycaemia. [<span class="referenceLink" id="referenceLink-25">25</span>]<span id="reference-25" class="content-reference">Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care November 2009, vol 32, no suppl 2 S2253-259</span>.&nbsp;Weight gain varies from person to person and the chance of gaining weight can be reduced by choosing foods carefully and being more active.</p>
<p><a href="../../../media_manager/public/150/images/Diabetes/15-in-100.jpg" class="image-reference">Fifteen out of 100</a> people taking insulin for Type 2 diabetes have symptoms of hypoglycaemia every week. Most of these don&rsquo;t need treatment in hospital. [<span class="referenceLink" id="referenceLink-26">26</span>]<span id="reference-26" class="content-reference">Hayward RA, Manning WG, Kaplan SH, et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications and resource utilization. JAMA 1997 Nov 26;278(20):1663-9</span></p>
<p>The chance of getting hypoglycaemia is lowest for people just starting on insulin. The longer people have been on insulin treatment the more likely they are to get hypos. [<span class="referenceLink" id="referenceLink-25">25</span>]<span id="reference-25" class="content-reference">Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care November 2009, vol 32, no suppl 2 S2253-259</span>.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-5" class="title" id="title-1635-5" tabindex="0">What are the potential health problems?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-5" aria-describedby="title-1635-5" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_4"><p>The main risk with insulin treatment is severe hypoglycaemia, when blood glucose goes very low. People having a severe hypo can lose consciousness and go into a coma. Without treatment they can die, although this is very rare. Severe hypos can be prevented or treated by taking sugary foods.</p>
<p>Just over <a href="../../../media_manager/public/150/images/Diabetes/16-100 (1).jpg" class="image-reference">16 in 100</a> people taking insulin for Type 2 diabetes say they have had at least one severe hypo. This is most likely to happen to people who don&rsquo;t understand how to avoid and treat hypoglycaemia. [<span class="referenceLink" id="referenceLink-28">28</span>]<span id="reference-28" class="content-reference">Akram K, Pedersen-Bjergaard U, Carstensen B. et al. Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: a cross-sectional survey. Diabet Med 2006 Jul;23(7):750-6</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-6" class="title" id="title-1635-6" tabindex="0">What are the effects on length of life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-6" aria-describedby="title-1635-6" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_5"><p>People with Type 2 diabetes may live longer on insulin. Over a 10-year period, people on insulin are 10% less likely to die of diabetic complications than people treated with diet alone. [<span class="referenceLink" id="referenceLink-23">23</span>]<span id="reference-23" class="content-reference">UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12;352(9131):837-53</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-7" class="title" id="title-1635-7" tabindex="0">What are the effects on diet, lifestyle and need for other treatments?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-7" aria-describedby="title-1635-7" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_6"><p>Some people taking insulin for Type 2 diabetes need to time their doses carefully in relation to meals, depending on the type of insulin they are taking. This is to make sure glucose from food is processed properly so that blood levels don&rsquo;t go too high or too low.</p>
<p>People with Type 2 diabetes can improve their diabetes control and reduce their chance of getting complications by improving their diet and lifestyle. [<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;These lifestyle changes are important whether or not they are taking medication for their diabetes.</p>
<p>The main ones are:</p>
<ul>
<li>being more physically active. Aerobic exercise, such as brisk walking or swimming, and resistance exercise, such as weight training, are both helpful;</li>
<li>having a healthy diet, with plenty of fruit, vegetables, wholegrains and pulses, low-fat dairy products and oily fish. [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul>
<p>Eating healthily and taking more exercise helps people lose weight, which can also help diabetes control.&nbsp;</p>
<p>People with Type 2 diabetes may also be advised to take other forms of medication to reduce their chance of getting complications.</p>
<p>These may include medications to: [<span class="referenceLink" id="referenceLink-32">32</span>]<span id="reference-32" class="content-reference">International Diabetes Federation. Global guideline for type 2 diabetes, 2012</span></p>
<ul>
<li>reduce high blood pressure</li>
<li>reduce blood fats</li>
<li>stop blood clotting that can lead to heart attacks or strokes.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1635-8" class="title" id="title-1635-8" tabindex="0">What are the effects on your life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1635-8" aria-describedby="title-1635-8" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1635_7"><p>Taking insulin changes people&rsquo;s lives in quite a few ways. They have to: [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></p>
<ul>
<li>learn how to inject themselves and gradually increase the dose of insulin until blood glucose has got down to safe levels</li>
<li>check their own blood glucose levels regularly to make sure they stay within safe limits, especially when driving</li>
<li>learn how to avoid and cope with hypoglycaemia, when blood glucose goes too low, and hyperglycaemia, when it goes too high.</li>
</ul>
<p>All of this may involve more frequent check-ups and meetings with the diabetes care team.&nbsp;</p>
<p>People treated with insulin face more driving restrictions than those taking other diabetes medications. [<span class="referenceLink" id="referenceLink-34">34</span>]<span id="reference-34" class="content-reference">Diabetes UK, Driving and diabetes, May 2009</span>&nbsp;</p>
<p>People who drive cars or motorcycles have to inform the Driving and Vehicle Licensing Agency (DVLA) when they start taking insulin. They have to renew their licenses every 1-3 years. &nbsp;</p>
<p>People who have Group 2 licences to drive larger vehicles, including large vans, lorries and buses, must inform the DVLA when they start insulin. They will need to stop using their Group 2 licence for at least 3 months whilst they are starting insulin. They may then be able to continue driving using their Group 2 licence, but will need to monitor their diabetes closely and have yearly medical assessments.</p>
<p>People can get further details about driving restrictions from their diabetes teams or the DVLA website.</p></div>
                    </dd>
                                                    </dl>
            </div>
        </div>
    </div>
        <div class="option-info-container" id="container-1633">
        <a id="option-1633-further-info">Further Information</a>
        <div class="insert-container">
            <div class="further-information">
                <h3 class="title">FURTHER INFORMATION ABOUT GLP-1 ANALOGUES</h3>
                <dl class="tabbed-container" id="info-1633" role="tablist">
                                                    <dt role="tab" aria-selected="false" aria-controls="content-1633-1" class="title" id="title-1633-1" tabindex="0">What are they?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-1" aria-describedby="title-1633-1" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_0"><p>GLP-1 analogues are injectable medications, including exenatide and liraglutide. They work by:</p>
<ul>
<li>helping the body make more insulin and less glucose</li>
<li>slowing the passage of glucose from the gut into the bloodstream.</li>
</ul>
<p>Both medications have to be injected into the skin of the stomach, thigh or upper arm. They come in short-acting forms, injected once or twice a day, and long-acting forms injected once a week.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-2" class="title" id="title-1633-2" tabindex="0">Who can choose them?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-2" aria-describedby="title-1633-2" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_1"><p>GLP-1 analogues are particularly suitable for people with weight problems because they can lead to weight loss.</p>
<p>People with Type 2 diabetes may be able to choose GLP-1 analogues if: [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span> [<span class="referenceLink" id="referenceLink-36">36</span>]<span id="reference-36" class="content-reference">NICE technology appraisal guidance 248. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes, February 2012</span></p>
<ul>
<li>they are already taking two types of glucose-lowering tablets and their blood glucose levels are still too high and</li>
<li>they are very overweight and their weight is causing problems or</li>
<li>taking insulin would affect their ability to work or they would benefit from losing weight.</li>
</ul>
<p>Being very overweight means having a body mass index (BMI) of 35 or more for people of European background. The levels may be higher or lower for other ethnic groups.</p>
<p>GLP-1 analogues should not be given to people with poor kidney function (eGFR less than 30), or with a previous history of pancreatitis. [<span class="referenceLink" id="referenceLink-37">37</span>]<span id="reference-37" class="content-reference">MHRA Drug safety update, volume 2, issue 8, March 2009</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-3" class="title" id="title-1633-3" tabindex="0">How effective are they?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-3" aria-describedby="title-1633-3" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_2"><p>GLP-1 analogues help to control blood glucose levels. &nbsp;[<span class="referenceLink" id="referenceLink-21">21</span>]<span id="reference-21" class="content-reference">NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span> [<span class="referenceLink" id="referenceLink-36">36</span>]<span id="reference-36" class="content-reference">NICE technology appraisal guidance 248. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes, February 2012</span> They can reduce HbA1c by around 10mmol/mol (1%). [<span class="referenceLink" id="referenceLink-40">40</span>]<span id="reference-40" class="content-reference">Wilding JPH, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. BMJ 2011;342:d410</span></p>
<p>Better control of blood glucose should reduce the chance of getting long term complications from diabetes. [<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span>.</p>
<p>The main complications are damage to the eyes, kidneys and nerves, as well as heart disease, peripheral artery disease and stroke.&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span>&nbsp;Reducing HbA1c levels by just 10mmol/mol (1%) cuts the chance of getting these complications by 21% (just over a fifth). [<span class="referenceLink" id="referenceLink-43">43</span>]<span id="reference-43" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes</span> [<span class="referenceLink" id="referenceLink-44">44</span>]<span id="reference-44" class="content-reference">UKPDS 35: prospective observational study. BMJ 2000; 321:405-12</span>.</p>
<p>GLP-1-analogues also help with weight loss. Losing weight may reduce the chance of getting heart disease.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-4" class="title" id="title-1633-4" tabindex="0">What are the main side effects?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-4" aria-describedby="title-1633-4" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_3"><p>People taking GLP-1 analogues sometimes get nausea, vomiting or headaches. They may also get itching or soreness around the injection site. Some people get more episodes of hypoglycaemia, when the blood glucose drops too low. [<span class="referenceLink" id="referenceLink-45">45</span>]<span id="reference-45" class="content-reference">NICE Clinical Guideline 66, Type 2 Diabetes, May 2008</span> [<span class="referenceLink" id="referenceLink-46">46</span>]<span id="reference-46" class="content-reference">NICE Technology appraisal guidance 248. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes, February 2012</span></p>
<p>People are most likely to get hypoglycaemia on the higher dose of short-acting exenatide (10 micrograms twice daily). <a href="../../../media_manager/public/150/images/Diabetes/28-in-100.jpg" class="image-reference">28 out of 100</a> people taking this dose along with metformin and sulfonylurea tablets will get a hypo within 30 weeks of starting treatment. This compares with <a href="../../../media_manager/public/150/images/Diabetes/19-100.jpg" class="image-reference">19 out of 100</a> on the lower dose of 5mcg twice daily and <a href="../../../media_manager/public/150/images/Diabetes/13-in-100.jpg" class="image-reference">13 out of 100</a> taking a dummy pill (placebo). [<span class="referenceLink" id="referenceLink-47">47</span>]<span id="reference-47" class="content-reference">Kendall DM, Riddle MC, Rosenstock J. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 May;28(5): 1083-91</span></p>
<p>The chance of getting hypoglycaemia can be reduced by lowering the dose of the sulfonylurea tablets.</p>
<p>&nbsp;</p>
<p>&nbsp;</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-5" class="title" id="title-1633-5" tabindex="0">What are the potential health problems?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-5" aria-describedby="title-1633-5" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_4"><p>There are two main risks from treatment with exenatide: [<span class="referenceLink" id="referenceLink-48">48</span>]<span id="reference-48" class="content-reference">MHRA Drug safety update vol 2, issue 8, March 2009</span></p>
<ul>
<li>Severe pancreatitis (inflammation of the pancreas), which can be fatal</li>
<li>Kidney problems, including kidney failure.</li>
</ul>
<p>People who get pancreatitis while taking exenatide will be taken off the treatment permanently.</p>
<p>People with poor kidney function should never have exenatide.</p>
<p>Liraglutide may increase the chance of getting pancreatitis and cancer. But there hasn&rsquo;t been enough research to say this for sure. [<span class="referenceLink" id="referenceLink-49">49</span>]<span id="reference-49" class="content-reference">Jeong KH, Yoo BK. The efficacy and safety of liraglutide. Int J Clin Pharm 2011 Oct;33(5):740-9</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-6" class="title" id="title-1633-6" tabindex="0">What are the effects on length of life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-6" aria-describedby="title-1633-6" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_5"><p>We can&rsquo;t say specifcally how treatment with GLP-1 analogues affects the life expectancy of people with Type 2 diabetes. There hasn&rsquo;t been enough research.</p>
<p>We can say that life expectancy is highest for people whose treatment keeps their HbA1c levels down to around 58mmol/mol, or 7.5%. [<span class="referenceLink" id="referenceLink-50">50</span>]<span id="reference-50" class="content-reference">Craig J, Peters JR, Tynan A. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-89</span></p>
<p>Life expectancy goes down progressively for people whose glucose levels are lower or higher than this.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-7" class="title" id="title-1633-7" tabindex="0">What are the effects on diet, lifestyle and need for other treatments </dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-7" aria-describedby="title-1633-7" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_6"><p>There are no special diet rules for people taking GLP-1 analogues&nbsp;but many people find their appetite will reduce with this treatment.</p>
<p>People taking exenatide twice-daily have to remember to inject themselves within the hour before their morning and evening meals.&nbsp;</p>
<p>People with Type 2 diabetes can improve their diabetes control and reduce their chance of getting complications by improving their diet and lifestyle. [<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;These lifestyle changes are important whether or not they are taking medication for their diabetes.</p>
<p>The main ones are:</p>
<ul>
<li>being more physically active. Aerobic exercise, such as brisk walking or swimming, and resistance exercise, such as weight training, are both helpful;</li>
<li>having a healthy diet, with plenty of fruit, vegetables, wholegrains and pulses, low-fat dairy products and oily fish. [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul>
<p>Eating healthily and taking more exercise helps people lose weight, which can also help diabetes control.&nbsp;</p>
<p>People with Type 2 diabetes may also be advised to take other forms of medication to reduce their chance of getting complications.</p>
<p>These may include drugs to: [<span class="referenceLink" id="referenceLink-32">32</span>]<span id="reference-32" class="content-reference">International Diabetes Federation. Global guideline for type 2 diabetes, 2012</span></p>
<ul>
<li>reduce high blood pressure</li>
<li>reduce blood fats</li>
<li>stop blood clotting that can lead to heart attacks or strokes.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1633-8" class="title" id="title-1633-8" tabindex="0">What are the effects on your life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1633-8" aria-describedby="title-1633-8" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1633_7"><p>People taking GLP-1 analogues as a third treatment may need to have their blood glucose levels and weight checked more frequently to see whether the treatment is working.</p>
<p>People with Group 2 licences who drive large vans, large goods vehicles or passenger carrying vehicles must inform the Driving and Vehicle Licensing Agency (DVLA) if they take GLP-1 analogues with sulfonylurea tablets. This is because of the increased chance of hypoglycaemia. [<span class="referenceLink" id="referenceLink-34">34</span>]<span id="reference-34" class="content-reference">Diabetes UK, Driving and diabetes, May 2009</span></p>
<p>The DVLA suggest people taking GLP-1 analogues in combination with sulfonylurea tablets test their blood sugars at least twice a day to monitor for hypoglycaemia. The DVLA considers each case individually after seeking information from people&rsquo;s diabetes team but sometimes they take people&rsquo;s licences away if they are having difficulties with their diabetes control and hypoglycaemia, or are not monitoring themselves well enough.</p>
<p>There are no restrictions for people holding Group 1 (car and motorcycle) licenses.</p></div>
                    </dd>
                                                    </dl>
            </div>
        </div>
    </div>
        <div class="option-info-container" id="container-1634">
        <a id="option-1634-further-info">Further Information</a>
        <div class="insert-container">
            <div class="further-information">
                <h3 class="title">FURTHER INFORMATION ABOUT PIOGLITAZONE</h3>
                <dl class="tabbed-container" id="info-1634" role="tablist">
                                                    <dt role="tab" aria-selected="false" aria-controls="content-1634-1" class="title" id="title-1634-1" tabindex="0">What is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-1" aria-describedby="title-1634-1" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_0"><p>This is a tablet treatment that works by making the cells of people's bodies more sensitive to insulin so they are better able to remove glucose from the blood.</p>
<p>Pioglitazone comes in two forms:</p>
<ul>
<li>on its own (Actos) when it is taken once daily before or after meals</li>
<li>in combination with metformin (Competact), when it has to be taken twice a day after meals.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-2" class="title" id="title-1634-2" tabindex="0">Who can choose it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-2" aria-describedby="title-1634-2" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_1"><p>People with Type 2 diabetes may be able to choose treatment with pioglitazone if: [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></p>
<ul>
<li>they are already taking metformin and sulfonylurea tablets and their blood glucose levels are still too high and</li>
<li>they are unwilling or unable to have insulin injections.</li>
</ul>
<p>People with Type 2 diabetes should not take pioglitazone if: [<span class="referenceLink" id="referenceLink-56">56</span>]<span id="reference-56" class="content-reference">MHRA Drug Safety Updates December 2007, August 2011</span></p>
<ul>
<li>they have bladder cancer or have had it in the past, or are at risk of bladder cancer</li>
<li>they have heart failure or have had it in the past</li>
<li>they have a high risk of bone fractures. [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-3" class="title" id="title-1634-3" tabindex="0">How effective is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-3" aria-describedby="title-1634-3" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_2"><p>Pioglitazone helps to control blood glucose levels. People using it in combination with other medications have seen their HBA1c levels drop by an average of 13.77mmol/mol (1.26%). [<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span></p>
<p>Better control of blood glucose should reduce the chance of getting long term complications from diabetes. [<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span></p>
<p>The main complications are damage to the eyes, kidneys and nerves, as well as heart disease, peripheral artery disease and stroke.&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span>&nbsp;Reducing HbA1c levels by just 10mmol/mol (%) cuts the chance of getting these complications by 21% (just over a fifth). [<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span>.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-4" class="title" id="title-1634-4" tabindex="0">What are the main side effects?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-4" aria-describedby="title-1634-4" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_3"><p>The main possible side effects of pioglitazone are:</p>
<ul>
<li>weight gain. People who took pioglitazone for 20 weeks gained an average of 2.7kg (6lb). [<span class="referenceLink" id="referenceLink-62">62</span>]<span id="reference-62" class="content-reference">Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care November 2009, vol 26, no 11, 3148-52</span>&nbsp;Weight gain varies from person to person and the chance of gaining weight can be reduced by choosing foods carefully and being more active.</li>
<li>fluid retention leading to swelling (oedema), particularly in the feet. [<span class="referenceLink" id="referenceLink-63">63</span>]<span id="reference-63" class="content-reference">Shah, P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 2010 Mar;9(2):347-54</span></li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-5" class="title" id="title-1634-5" tabindex="0">What are the potential health problems?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-5" aria-describedby="title-1634-5" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_4"><p>People with Type 2 diabetes who take pioglitazone may have a small increased chance of getting bladder cancer (around 1 extra case of bladder cancer in every 1000 people taking pioglitazone). [<span class="referenceLink" id="referenceLink-64">64</span>]<span id="reference-64" class="content-reference">MHRA Drug safety update, vol 5, issue 1, August 2011</span></p>
<p>It should not be used by people who:</p>
<ul>
<li>have bladder cancer now</li>
<li>had it in the past</li>
<li>have blood in their urine.</li>
</ul>
<p>Elderly people, who have a higher chance of getting bladder cancer, should start on the lowest possible dose and have regular check-ups.</p>
<p>In some people taking pioglitazone fluid retention can cause or worsen heart failure. [<span class="referenceLink" id="referenceLink-65">65</span>]<span id="reference-65" class="content-reference">MHRA drug safety update, vol 1, issue 5, December 2007</span>. This is most likely in people who are also taking insulin or sulfonylurea tablets.</p>
<p>Pioglitazone should not be used by people who have heart failure or have had it in the past. People at risk of heart failure should start pioglitazone at the lowest possible dose and be watched closely for warning signs that mean the drug should be stopped.</p>
<p>Pioglitazone also increases the chance of getting bone fractures, particularly in women. Just under <a href="../../../media_manager/public/150/images/Diabetes/6-in-100.jpg" class="image-reference">6 in 100</a> women treated with pioglitazone or a similar drug called rosiglitazone for up to four years had fractures compared with <a href="../../../media_manager/public/150/images/Diabetes/3-100.jpg" class="image-reference">3 in 100</a> women treated with other drugs. [<span class="referenceLink" id="referenceLink-66">66</span>]<span id="reference-66" class="content-reference">Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009 Jan 6;180(1):32-9</span></p>
<p>Doctors are no longer allowed to prescribe rosiglitazone for Type 2 diabetes because in increases the chance of getting heart attacks as well as heart failure. [<span class="referenceLink" id="referenceLink-67">67</span>]<span id="reference-67" class="content-reference">MHRA Drug safety update, vol 4, issue 3, October 2010</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-6" class="title" id="title-1634-6" tabindex="0">What are the effects on length of life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-6" aria-describedby="title-1634-6" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_5"><p>We can&rsquo;t say specifcally how treatment with pioglitazone affects the life expectancy of people with Type 2 diabetes. There hasn&rsquo;t been enough research.</p>
<p>We can say that life expectancy is highest for people whose treatment keeps their HbA1c levels down to around 58mmol/mol, or 7.5%. [<span class="referenceLink" id="referenceLink-50">50</span>]<span id="reference-50" class="content-reference">Craig J, Peters JR, Tynan A. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-89</span></p>
<p>Life expectancy goes down progressively for people whose glucose levels are lower or higher than this.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-7" class="title" id="title-1634-7" tabindex="0">What are the effects on diet, lifestyle and need for other treatments?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-7" aria-describedby="title-1634-7" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_6"><p>There are no special diet rules for people taking pioglitazone.</p>
<p>People with Type 2 diabetes can improve their diabetes control and reduce their chance of getting complications by improving their diet and lifestyle. [<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;</p>
<p>These lifestyle changes are important whether or not they are taking medication for their diabetes.</p>
<p>The main ones are:</p>
<ul>
<li>being more physically active. Aerobic exercise, such as brisk walking or swimming, and resistance exercise, such as weight training, are both helpful;</li>
<li>having a healthy diet, with plenty of fruit, vegetables, wholegrains and pulses, low-fat dairy products and oily fish. [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul>
<p>Eating healthily and taking more exercise helps people lose weight, which can also help diabetes control. This is particularly important with pioglitazone because people taking it tend to gain weight.</p>
<p>People with Type 2 diabetes may also be advised to take other forms of medication to reduce their chance of getting complications. These may include medications to: [<span class="referenceLink" id="referenceLink-32">32</span>]<span id="reference-32" class="content-reference">International Diabetes Federation. Global guideline for type 2 diabetes, 2012</span></p>
<ul>
<li>reduce high blood pressure</li>
<li>reduce blood fats</li>
<li>stop blood clotting that can lead to heart attacks or strokes.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1634-8" class="title" id="title-1634-8" tabindex="0">What are the effects on your life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1634-8" aria-describedby="title-1634-8" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1634_7"><p>People taking pioglitazone as a third treatment may need extra health checks because of the increased chance of getting bladder cancer, heart failure or bone fractures.</p>
<p>There are no driving restrictions for people taking pioglitazone combined with other tablet treatments. [<span class="referenceLink" id="referenceLink-34">34</span>]<span id="reference-34" class="content-reference">Diabetes UK, Driving and diabetes, May 2009</span></p></div>
                    </dd>
                                                    </dl>
            </div>
        </div>
    </div>
        <div class="option-info-container" id="container-1632">
        <a id="option-1632-further-info">Further Information</a>
        <div class="insert-container">
            <div class="further-information">
                <h3 class="title">FURTHER INFORMATION ABOUT DDP-4 INHIBITORS</h3>
                <dl class="tabbed-container" id="info-1632" role="tablist">
                                                    <dt role="tab" aria-selected="false" aria-controls="content-1632-1" class="title" id="title-1632-1" tabindex="0">What is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-1" aria-describedby="title-1632-1" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_0"><p>DDP-4 inhibitor tablets, also known as &lsquo;gliptins&rsquo;, include sitaglipin and vildagliptin. They work by:</p>
<ul>
<li>helping the body make more insulin and less glucose</li>
<li>slowing the passage of glucose from the gut into the bloodstream</li>
<li>making people feel full so they don&rsquo;t eat as much.</li>
</ul>
<p>The tablets are taken once a day, with or without food.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-2" class="title" id="title-1632-2" tabindex="0">Who can choose it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-2" aria-describedby="title-1632-2" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_1"><p>People with Type 2 diabetes may be able to choose treatment with DDP-4 inhibitors if they are already taking metformin and sulfonylurea tablets and their blood glucose levels are still high. [<span class="referenceLink" id="referenceLink-21">21</span>]<span id="reference-21" class="content-reference">NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span></p>

<p>Pregnant women and breastfeeding mothers should not have DDP-4 inhibitors. We don&rsquo;t yet know how safe they are for mothers and babies.</p>
<p>They should not be given to people with poor kidney function (eGFR less than 30).&nbsp;</p>
<p>These tablets don't usually lead to weight gain, so may be particularly right for people who are already overweight, or are worried about weight gain.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-3" class="title" id="title-1632-3" tabindex="0">How effective is it?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-3" aria-describedby="title-1632-3" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_2"><p>DDP-4 inhibitors work well at controlling blood glucose levels. People taking them find their HbA1c levels drop by about 7.65mmol/mol (0.7%). [<span class="referenceLink" id="referenceLink-74">74</span>]<span id="reference-74" class="content-reference">Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 Apri 16;(2):CD006739</span></p>
<p>Better control of blood glucose should reduce the chance of getting long term complications from diabetes. [<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span>. The main complications are damage to the eyes, kidneys and nerves, as well as heart disease, peripheral artery disease and stroke.&nbsp;[<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span>&nbsp;Reducing HbA1c levels by just 10mmol/mol (1%) cuts the chance of getting these complications by 21% (just over a fifth). [<span class="referenceLink" id="referenceLink-5">5</span>]<span id="reference-5" class="content-reference">Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405-12</span>.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-4" class="title" id="title-1632-4" tabindex="0">What are the main side effects?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-4" aria-describedby="title-1632-4" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_3"><p>Taking DDP-4 inhibitors as a third treatment may increase the chance of having a hypoglycaemic episode (&lsquo;hypo&rsquo;). <a href="../../../media_manager/public/150/images/Diabetes/16-100 (1).jpg" class="image-reference">Sixteen out of 100</a> people taking them with metformin and sulfonylurea tablets will get a hypo within 24 weeks of starting treatment compared with <a href="../../../media_manager/public/150/images/Diabetes/1-100.jpg" class="image-reference">1 in 100</a> taking a dummy pill (placebo). [<span class="referenceLink" id="referenceLink-21">21</span>]<span id="reference-21" class="content-reference">NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span><br />They don't seem to increase the chance of having severe hypos. [<span class="referenceLink" id="referenceLink-74">74</span>]<span id="reference-74" class="content-reference">Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 Apri 16;(2):CD006739</span></p>
<p>People taking DDP-4 inhibitors may gain very small amounts of weight &ndash; less than half a kg after 24 weeks treatment &ndash; or none at all. [<span class="referenceLink" id="referenceLink-21">21</span>]<span id="reference-21" class="content-reference">NICE Short Clinical Guideline 87. Type 2 diabetes: newer agents. Issued May 2009</span> [<span class="referenceLink" id="referenceLink-74">74</span>]<span id="reference-74" class="content-reference">Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008 Apri 16;(2):CD006739</span></p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-5" class="title" id="title-1632-5" tabindex="0">What are the potential health problems?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-5" aria-describedby="title-1632-5" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_4"><p>Some people taking one of these drugs, sitagliptin, have had attacks of acute pancreatitis. This is a serious inflammation of the pancreas, the organ that makes insulin. [<span class="referenceLink" id="referenceLink-82">82</span>]<span id="reference-82" class="content-reference">MHRA Drug Safety Update, vol 6, issue 2, September 2012</span>.</p>
<p>When sitagliptin is prescribed, people are told to watch out for the main sign of this condition &ndash; severe abdominal pain, sometimes felt in the back &ndash; and report it immediately to their doctors.<br />If pancreatitis is suspected they have to stop taking the medication.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-6" class="title" id="title-1632-6" tabindex="0">What are the effects on length of life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-6" aria-describedby="title-1632-6" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_5"><p>We can&rsquo;t say specifcally how treatment with DDP-4 inhibitors affects the life expectancy of people with Type 2 diabetes. There hasn&rsquo;t been enough research.</p>
<p>We can say that life expectancy is highest for people whose treatment keeps their HbA1c levels down to around 58mmol/mol, or 7.5%. [<span class="referenceLink" id="referenceLink-50">50</span>]<span id="reference-50" class="content-reference">Craig J, Peters JR, Tynan A. et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-89</span><br />Life expectancy goes down progressively for people whose glucose levels are lower or higher than this.</p></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-7" class="title" id="title-1632-7" tabindex="0">What are the effects on diet, lifestyle and need for other treatments </dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-7" aria-describedby="title-1632-7" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_6"><p>There are no special diet rules for people taking DDP-4 inhibitors for Type 2 diabetes. They can be taken at any time of the day, not linked to meal times.</p>
<p>People with Type 2 diabetes can improve their diabetes control and reduce their chance of getting complications by improving their diet and lifestyle. [<span class="referenceLink" id="referenceLink-10">10</span>]<span id="reference-10" class="content-reference">Scottish Intercollegiate Guidelines Network. Management of Diabetes, March 2010</span>&nbsp;These lifestyle changes are important whether or not they are taking medication for their diabetes.</p>
<p>The main ones are:</p>
<ul>
<li>being more physically active. Aerobic exercise, such as brisk walking or swimming, and resistance exercise, such as weight training, are both helpful;</li>
<li>having a healthy diet, with plenty of fruit, vegetables, wholegrains and pulses, low-fat dairy products and oily fish. [<span class="referenceLink" id="referenceLink-3">3</span>]<span id="reference-3" class="content-reference">NICE Clinical Guideline 66,Type 2 Diabetes, May 2008</span></li>
</ul>
<p>Eating healthily and taking more exercise helps people lose weight, which can also help with diabetes control.</p>
<p>People with Type 2 diabetes may also be advised to take other forms of medication to reduce their chance of getting complications. These may include medications to: [<span class="referenceLink" id="referenceLink-32">32</span>]<span id="reference-32" class="content-reference">International Diabetes Federation. Global guideline for type 2 diabetes, 2012</span></p>
<ul>
<li>reduce high blood pressure</li>
<li>reduce blood fats</li>
<li>stop blood clotting that can lead to heart attacks or strokes.</li>
</ul></div>
                    </dd>
                                                        <dt role="tab" aria-selected="false" aria-controls="content-1632-8" class="title" id="title-1632-8" tabindex="0">What are the effects on your life?</dt>
                    <dd role="tabpanel" aria-hidden="true" id="content-1632-8" aria-describedby="title-1632-8" class="further-info-tab-content">
                        <div data-cms-content-id="349_2_further-info_1632_7"><p>People with Group 2 licences to drive large goods vehicles or passenger carrying vehicles must inform the Driving and Vehicle Licensing Agency (DVLA) if they take DDP-4 inhibitors with sulfonylurea tablets. This is because of the increased chance of hypoglycaemia.&nbsp;[<span class="referenceLink" id="referenceLink-34">34</span>]<span id="reference-34" class="content-reference">Diabetes UK, Driving and diabetes, May 2009</span></p>
<p>The DVLA considers each case individually after consulting people&rsquo;s diabetes team. Sometimes they have to take people&rsquo;s licences away.</p></div>
                    </dd>
                                                    </dl>
            </div>
        </div>
    </div>
    </div></div>            <form method="post">
                                <input type="hidden" name="_submitValues" value="1" />
                <div class="introduction">
                                                                <div class="my-values-introduction">
                            <p>Before making a decision it is important that you consider the consequences of each of the available options.</p>
<p>If at this point you are NOT SURE about your decision, more help is available. We have prepared a number of lifestyle related statements. Choosing how you feel about each of the statements will help you think about how important these potential consequences are to you.</p>                            <a id="show-values-form" class="big-button" href="../my-trade-offs/index.html">I NEED MORE HELP BEFORE MAKING MY DECISION<span>Show me the statements</span></a>
                       <p>If you are ALREADY SURE about your decision, you can proceed to STEP 5 &mdash; My decision.</p>                            <a class="big-button big-button-grey" href="../my-decision/index.html">IM READY TO MAKE MY DECISION<span>Proceed to STEP 5  My Decision</span></a>    
                        </div>
                                                            <div class="my-values-step-content">
                        <p>Before making a decision it is important that you consider the consequences of each of the available options. Choosing&nbsp;how you feel about each of the statements below will help you think about how important these potential consequences are to you.</p>                        <div class="values-form">
                                                    <div class="statement" data-cms-content-id="349_3_view_1658">
                                <dt id="viewOptions-1658-label"><label for="viewOptions[1658]" class="required">The most important thing to me is avoiding complications of diabetes</label></dt><dd id="viewOptions-1658-element"><div class="radio-option"><input type="radio" name="viewOptions[1658]" value="1" class="option" id="disagree-strongly-1658"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1658]" value="2" class="option" id="disagree-somewhat-1658"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1658]" value="3" class="option" id="agree-somewhat-1658"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1658]" value="4" class="option last" id="agree-strongly-1658"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                    <div class="statement" data-cms-content-id="349_3_view_1657">
                                <dt id="viewOptions-1657-label"><label for="viewOptions[1657]" class="required">I want my treatment to have as little impact on my life as possible</label></dt><dd id="viewOptions-1657-element"><div class="radio-option"><input type="radio" name="viewOptions[1657]" value="1" class="option" id="disagree-strongly-1657"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1657]" value="2" class="option" id="disagree-somewhat-1657"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1657]" value="3" class="option" id="agree-somewhat-1657"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1657]" value="4" class="option last" id="agree-strongly-1657"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                    <div class="statement" data-cms-content-id="349_3_view_1656">
                                <dt id="viewOptions-1656-label"><label for="viewOptions[1656]" class="required">It is important to me to avoid hypoglycaemic episodes</label></dt><dd id="viewOptions-1656-element"><div class="radio-option"><input type="radio" name="viewOptions[1656]" value="1" class="option" id="disagree-strongly-1656"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1656]" value="2" class="option" id="disagree-somewhat-1656"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1656]" value="3" class="option" id="agree-somewhat-1656"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1656]" value="4" class="option last" id="agree-strongly-1656"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                    <div class="statement" data-cms-content-id="349_3_view_1655">
                                <dt id="viewOptions-1655-label"><label for="viewOptions[1655]" class="required">I want my treatment to be safe and without side effects</label></dt><dd id="viewOptions-1655-element"><div class="radio-option"><input type="radio" name="viewOptions[1655]" value="1" class="option" id="disagree-strongly-1655"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1655]" value="2" class="option" id="disagree-somewhat-1655"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1655]" value="3" class="option" id="agree-somewhat-1655"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1655]" value="4" class="option last" id="agree-strongly-1655"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                    <div class="statement" data-cms-content-id="349_3_view_1654">
                                <dt id="viewOptions-1654-label"><label for="viewOptions[1654]" class="required">I am unwilling to have a treatment that will make me put on weight</label></dt><dd id="viewOptions-1654-element"><div class="radio-option"><input type="radio" name="viewOptions[1654]" value="1" class="option" id="disagree-strongly-1654"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1654]" value="2" class="option" id="disagree-somewhat-1654"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1654]" value="3" class="option" id="agree-somewhat-1654"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1654]" value="4" class="option last" id="agree-strongly-1654"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                    <div class="statement" data-cms-content-id="349_3_view_1653">
                                <dt id="viewOptions-1653-label"><label for="viewOptions[1653]" class="required">I don&rsquo;t like the thought of injections</label></dt><dd id="viewOptions-1653-element"><div class="radio-option"><input type="radio" name="viewOptions[1653]" value="1" class="option" id="disagree-strongly-1653"  /><span class="label">Disagree strongly</span></div><div class="radio-option"><input type="radio" name="viewOptions[1653]" value="2" class="option" id="disagree-somewhat-1653"  /><span class="label">Disagree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1653]" value="3" class="option" id="agree-somewhat-1653"  /><span class="label">Agree somewhat</span></div><div class="radio-option"><input type="radio" name="viewOptions[1653]" value="4" class="option last" id="agree-strongly-1653"  /><span class="label">Agree strongly</span></div></dd>                            </div>
                                                </div>
                    </div>
                                                                    <div class="navigation">
        <div class="nav-link previous">
                    <div class="button-wrap">
                                <a href="../compare-options/index.html">GO BACK</a>
                            </div>
                    <!--  a id="progressSummary" class="button" title="My progress/print summary" href="/pda/diabetes-additional-treatments-to-improve-control/progress-summary/" role="button">MY PROGRESS / PRINT SUMMARY</a --></div>
        <div class="nav-link next">
                    <input type="hidden" name="nextUrl" value="/pda/diabetes-additional-treatments-to-improve-control/my-trade-offs/" />
            <div class="button-wrap" id="saveAndContinue">
                <a href="../my-trade-offs/index.html">CONTINUE</a>
            </div>
                </div>
    </div>
                                                    </div>
            </form>
        </div>
    </div>
</div>
<script type="text/javascript" src="../../../javascript/values.js"></script>
<script type="text/javascript">
/*<![CDATA[*/
Nhs.Pda.init({
    "baseUrl": '/pda/diabetes-additional-treatments-to-improve-control',
    "sectionId": 3,
    'pageId': 349,
    'pelorousSectionId':  147,
    'help': 'embedded',
    "autoPlayId": "play-your-views"
});
/*]]>*/
</script></div>
<div class="yui-g">
<div id="mag-feedback"> <!-- start mag-feedback -->

</div> <!-- end mag-feedback -->
</div>
</div> <!-- end yui bd -->

<div id="ft"> <!-- start yui ft -->
<div id="footer"> <!-- start footer -->
<div class="footer-content">
<div class="section general-column"><div class="snippet-sub-heading"></div>
<div class="snippet-partners"></div><div class="snippet-sitemap">
<ul class="sitemap">
<li class="firstItem">
<a class="link" href="http://www.nhs.uk/aboutNHSChoices/Pages/ContactUs.aspx" target="_blank">Feedback form</a>
</li>
<li class="lastItem">
<a class="link" href="../../../privacy-policy/index.html">Privacy Policy</a>
</li>
</ul>
</div>
<div class="snippet-copyright-information">
<div class="text">
<p>&copy; NHS Choices 2013.</p>
</div>
</div>
</div>

</div>

</div> <!-- end footer -->
 </div> <!-- end yui ft -->

</div> <!-- end yui doc -->
<script type="text/javascript">
var _gaq = _gaq || [];
_gaq.push(["_setAccount", "UA-32468195-1"]);
_gaq.push(["_trackPageview"]);
_gaq.push(["_trackPageLoadTime"]);
(function() {
var ga = document.createElement("script");
ga.type = "text/javascript"; ga.async = true;
ga.src = ("https:" == document.location.protocol ? "https://ssl" : "http://www") + ".google-analytics.com/ga.js";
var s = document.getElementsByTagName("script")[0];
s.parentNode.insertBefore(ga, s);
})();
</script>
</body>
</html>
